Horizon Kinetics Asset Management LLC Buys 8,330 Shares of Royalty Pharma PLC $RPRX

Horizon Kinetics Asset Management LLC raised its stake in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 353,191 shares of the biopharmaceutical company’s stock after acquiring an additional 8,330 shares during the period. Horizon Kinetics Asset Management LLC owned approximately 0.06% of Royalty Pharma worth $20,612,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of RPRX. Bank of America Corp DE increased its position in shares of Royalty Pharma by 29.0% in the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock worth $167,696,000 after purchasing an additional 786,921 shares during the period. Amundi raised its stake in Royalty Pharma by 15.3% in the first quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock valued at $148,168,000 after purchasing an additional 409,394 shares in the last quarter. Dorsey Asset Management LLC raised its stake in Royalty Pharma by 0.8% in the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock valued at $109,207,000 after purchasing an additional 17,101 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Royalty Pharma by 28.2% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,168,427 shares of the biopharmaceutical company’s stock worth $68,189,000 after purchasing an additional 256,841 shares during the period. Finally, Danske Bank A S lifted its position in Royalty Pharma by 44.4% during the third quarter. Danske Bank A S now owns 1,107,117 shares of the biopharmaceutical company’s stock worth $64,611,000 after purchasing an additional 340,439 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Royalty Pharma news, CFO Terrance P. Coyne sold 232,536 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $68.87, for a total value of $16,014,754.32. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 440,788 shares of company stock worth $29,157,162 in the last three months. 18.84% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RPRX. The Goldman Sachs Group reiterated a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. TD Cowen boosted their target price on shares of Royalty Pharma from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Research raised shares of Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. Citigroup increased their price target on shares of Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Finally, Morgan Stanley lifted their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $65.00.

Get Our Latest Stock Report on Royalty Pharma

Royalty Pharma Stock Up 1.1%

Shares of NASDAQ RPRX opened at $68.47 on Friday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.77. The company has a market cap of $39.28 billion, a price-to-earnings ratio of 57.06, a PEG ratio of 1.36 and a beta of 0.37. Royalty Pharma PLC has a 12 month low of $37.31 and a 12 month high of $70.37. The stock has a 50-day moving average price of $62.31 and a two-hundred day moving average price of $55.20.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, November 13th. Royalty Pharma’s dividend payout ratio is currently 78.33%.

About Royalty Pharma

(Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Featured Stories

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.